Lead Product(s): GFB-887
Therapeutic Area: Nephrology Product Name: GFB-887
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Eventide Asset Management
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 30, 2020
Proceeds from the Series B financing will enable the advancement of GFB-887 and GFB-024 through three potential clinical proof-of-concept readouts and will also support continued development of the Company’s discovery platform and preclinical pipeline.
Lead Product(s): BION-1301
Therapeutic Area: Nephrology Product Name: BION-1301
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020
Part 3 of the Phase 1 multi-center trial is evaluating the safety and tolerability of BION-1301 in two cohorts of 20 total adult subjects with IgA nephropathy in an open-label multiple dose design.